Strategic Partnerships Cosylab's proven track record with CERN, ITER, Mayo Clinic and Leo Cancer Care positions it as a trusted partner for large research facilities and major medical device manufacturers. There is a clear opportunity to cross-sell control systems, data integration and planning modules to these partners and their ecosystems.

Therapy Focus Recent product launches and LOIs indicate a growing specialization in accelerator-based cancer therapies, including PlanOne for particle therapy and BNCT deployment. Target buyers include proton therapy and BNCT centers, hospital oncology programs, and research institutions building new treatment capabilities, offering planning, control and integration software.

Turnkey Advantage Cosylab emphasizes end-to-end software and electronics for complex systems, enabling hospitals and labs to shorten development cycles and achieve faster time-to-market. This can be pitched to medical device manufacturers seeking integrated control software and to research centers needing seamless workflow integration from planning to operation.

Global Footprint With EU headquarters and subsidiaries across Europe, North America and Asia, Cosylab can support multi-region deployments and comply with diverse regulatory environments. This makes it attractive for global labs, consortia and manufacturers pursuing worldwide installations.

Growth Signals Recent 2026 announcements signal a growth trajectory in treatment planning and accelerator-based systems, backed by credible partnerships and an expanding client base. Opportunities exist to engage other BNCT and accelerator facilities, universities and cancer centers seeking integrated software platforms for planning, control and data management.